Skip to main content

Table 2 Presenting symptoms and pulmonary function data across the entire cohort (N = 51) and the women-only cohort (N = 40)

From: Is the combination of bilateral pulmonary nodules and mosaic attenuation on chest CT specific for DIPNECH?

  Entire cohort
(N = 51)
Women-only (N = 40)
Presenting symptom(s)
 Cough 6 (12) 5 (13)
 Cough and dyspnea 7 (14) 6 (15)
 Wheezing 1 (2) 1 (3)
 Hemoptysis 1 (2) 1 (3)
 Dyspnea 11 (22) 10 (25)
 Post-transplant surveillance 4 (8) 2 (5)
 Incidental CT findings 21 (41) 15 (38)
Duration of respiratory symptoms, months
 Median [IQR] 16 [4–72] 19 [4–72]
Pulmonary function testing¥
PFT pattern N = 39 N = 33
 Normal 12 (31) 11 (33)
 Obstructive 10 (26) 9 (27)
 Restrictive 11 (28) 7 (21)
 Mixed 0 (0) 0 (0)
 Nonspecific 6 (15) 6 (18)
Severity of respiratory impairment N = 27 N = 22
 ≥ 70% predicted 11 (41) 8 (36)
 60–69% predicted 8 (30) 7 (32)
 50–59% predicted 3 (11) 3 (14)
 35–49% predicted 3 (11) 2 (9)
 < 35% predicted 2 (7) 2 (9)
Air trapping and hyperinflation
 Patients with lung volume measurements N = 31 N = 26
 Air trapping present 10 (32) 9 (35)
 Hyperinflation present 3 (10) 3 (12)
Diffusing capacity
 Patients with lung volume measurements N = 31 N = 26
 DLCO reduced 15 (48) 12 (46)
 Degree of DLCO reduction (% predicted); median [IQR] 51 [48–61] 50 [45–61]
 Bronchodilator responsiveness
 Patients with BD responsiveness testing N = 26 N = 22
 Positive BD response 5 (19) 5 (23)
 Negative BD response 21 (81) 17 (77)
  1. Data are presented as N (%) unless otherwise specified
  2. CT computed tomography, IQR interquartile range, PFT pulmonary function test, FEV1 forced expiratory volume in 1st second, DLCO diffusing capacity of carbon monoxide, BD bronchodilator
  3. ¥Excluding the 4 lung transplant recipients
  4. Severity is determined by FEV1% of predicted value